Form 4: Theravance Biopharma SVP & CFO Sells Shares to Cover Tax Obligations

Aziz Sawaf, SVP & CFO of Theravance Biopharma, sold 8,477 ordinary shares to cover tax obligations related to vesting restricted stock units.

Summary

• Aziz Sawaf, the Senior Vice President and Chief Financial Officer of Theravance Biopharma, sold 8,477 ordinary shares of the company.
• The sale was executed on November 20, 2024, at a price of $9.97 per share.
• This transaction was not an open market sale but rather a withholding of shares by the company to cover tax obligations arising from the vesting of previously granted restricted stock units.
• Following the transaction, Mr. Sawaf beneficially owns 312,889 ordinary shares.

Sentiment

Score: 5

Explanation: The document reflects a neutral event, a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• Share sales by executives to cover tax obligations are a common practice across the industry.
• The transaction is consistent with standard procedures for handling restricted stock unit vesting.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Theravance Biopharma, Aziz Sawaf, share sale, tax obligations, restricted stock units, insider transaction, Form 4